Bone News and Research

RSS

AML patient raises awareness in community about national stem cell registry

By the age of 28, Dana Severson was already an Iraq war veteran, an accomplished clinical engineer, a wife and mother. Days following her daughter Genevieve's first birthday, Severson was faced with a reality that would turn her life upside down. After several weeks of experiencing severe headaches and extreme exhaustion, the young mother was diagnosed with acute myeloid leukemia.

16 Feb 2011

Bisphosphonates appear to reduce risk of postmenopausal colorectal cancer by 50%

An international team of researchers has found that the use of bisphosphonates - drugs already taken by millions of healthy women to prevent bone-loss - for more than one year was associated with a 50 percent reduction in the risk of postmenopausal colorectal cancer. The results were published this week in the Journal of Clinical Oncology.

15 Feb 2011

FDA clears ArthroCare's Spartan 5.5 Needled Anchor

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has received clearance from the U.S. Food and Drug Administration for its Spartan 5.5 Needled Anchor. Spartan is a preloaded threaded anchor indicated for use in fixation of soft tissue to bone, such as during a rotator cuff repair.

15 Feb 2011

Viewing knee as an organ could lead to better therapies for treatment of osteoarthritis

The human body is made up of several organs composed of tissues that enable them to perform a particular function. The heart circulates blood; the brain is the micro-neuro center of the body; the lungs bring in oxygen and release carbon dioxide.

15 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

Sonoma announces closing of $22 million Series D financing

Sonoma Orthopedic Products announced that it has closed a $22 million Series D financing round led by Ascension Health Ventures (AHV). Also participating in the round were Split Rock Partners, Legacy Life Sciences, EDF Ventures, MedVenture Associates, DFJ InCube Ventures, Emergent Medical Partners, and Asset Management Partners.

14 Feb 2011

Oral bisphosphonates outweigh the risk associated with jaw disease

A commonly prescribed osteoporosis drug is associated with a slightly elevated risk of developing the rare, but serious condition, osteonecrosis of the jaw; nonetheless the risk remains extremely low. These findings are published online in the Journal of Dental Research, the official journal of the International and American Associations for Dental Research.

14 Feb 2011

Harmful effects of energy drinks on children

A new study published in the journal Pediatrics on Monday examined the risks of consumption of high-caffeine energy drinks on children and young adults. The study notes that these drinks are linked to an array of serious events like heart palpitations, high blood pressure and even cardiac arrest and death. The risk rises if young adults consuming the drink suffer from chronic diseases or take other medications.

14 Feb 2011

Corgenix second quarter revenues decrease 8.9%

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues slightly declined during the quarter but were more than offset by decreases in operating expenses and interest expense, resulting in a smaller net loss for the period.

14 Feb 2011

FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's NurOwn™ autologous adult stem cell product candidate for the treatment of amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's Disease.

14 Feb 2011

Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.

14 Feb 2011

Expensive 'high tech' therapy not superior to home training for walking recovery of stroke survivors

Home-based physical therapy to improve the strength and balance of stroke survivors works about as well to get them walking again as treadmill training done in a physical therapy lab, according to the results of a study presented today by a Duke researcher at the American Stroke Association's International Stroke Conference.

14 Feb 2011

JDR releases research report on Osteonecrosis of the jaw

Osteonecrosis of the jaw is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. The literature in this area has been severely limited since most investigations cannot evaluate sufficient numbers of afflicted individuals to accurately determine the incidence of the disease and associated risk factors.

14 Feb 2011

New clinical trial to test surgery specifically for Type 2 diabetes

A new clinical trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is among the first to test surgery specifically for Type 2 diabetes. The aim of the study is to understand whether surgery can control diabetes, as well or even better than the best medical treatment available today. This is the first study of its kind open to patients who are overweight or mildly obese.

14 Feb 2011

Sonoma acquires NovaLign Orthopaedics

Sonoma Orthopedic Products announced that it has completed the acquisition of certain key assets of NovaLign Orthopaedics, Inc.

14 Feb 2011

Women need good nutrition and regular exercise

Obesity levels are at an all-time high among men, women, and children in the United States. The need for good nutrition and regular exercise is paramount for maintaining proper health and for keeping those extra pounds at bay, especially for women.

11 Feb 2011

FDA grants Stryker 510(k) clearance for MDM X3 Mobile Bearing Hip System

Stryker Corporation's Orthopaedics Division today announced U.S. Food and Drug Administration 510(k) clearance for its MDM X3 Modular Dual Mobility Mobile Bearing Hip System. MDM X3 is an addition to the company's portfolio of next-generation technologies designed to minimize the risks traditionally associated with hip replacement surgery and address a broader patient population, including both primary and revision total hip arthroplasty candidates.

From Stryker 11 Feb 2011

New perspectives challenge long-held beliefs about impact of saturated fatty acids on risk of cardiovascular disease

For generations, the consumption of dairy products has been positively associated with the health and wellness of families and communities. Nevertheless, the recent shift in dietary trends has focused on "what not to eat" instead of emphasizing "what to eat," resulting in demonizing the naturally occurring fats in dairy, while overlooking its many essential nutrients.

11 Feb 2011

AAOS appreciates FDA's communication on metal-on-metal hip components in total hip arthroplasty

The U.S. Food and Drug Administration (FDA) today posted a public health communication about metal-on-metal hip components used in total hip arthroplasty (THA). The American Academy of Orthopaedic Surgeons (AAOS) appreciates this thorough and well-considered look at the concerns surrounding the use of these implants.

11 Feb 2011